Literature DB >> 10478988

Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO.

S P Amin1, C D Mullins, B S Duncan, L Blandford.   

Abstract

The differences in direct health care costs and use between HMO enrollees with both diabetes mellitus and hypertension and enrollees with either disease alone were studied. Two years' worth of medical and pharmacy claims data from a hybrid (independent practice association and group)-model HMO were evaluated. Diagnoses were determined from medical claims data and cross-referenced with prescription information from pharmacy claims data. Aggregate costs associated with each disease, including pharmacy costs, costs of physician office visits, and laboratory costs, were compiled. Comparisons were made of all costs (any cost incurred by the health plan for the member, regardless of disease) and disease-specific costs. The frequency of comorbid conditions was identified. A total of 6195 patients (670 with diabetes and hypertension, 1756 with diabetes alone, and 3769 with hypertension alone) were assessed. Patients with both diseases incurred much higher costs per year than patients with diabetes or hypertension alone (mean costs, $13,446, $8,493, and $8,424, respectively). Hospitalization costs contributed the greatest amount to total costs, while emergency room costs contributed the least. Disease-specific costs for diabetes and hypertension represented less than one quarter of total health care costs per patient. Average disease-specific costs were highest for patients with both diseases ($2,955), followed by costs for patients with hypertension alone ($1,803) and patients with diabetes alone ($689). The percentage spent on prescriptions was much higher for disease-specific costs than for total costs. The three most common comorbid conditions were dyslipidemia, coronary artery disease, and chronic obstructive pulmonary disease, with the frequency of cerebrovascular disease and myocardial infarction more than double in patients with diabetes and hypertension compared with patients with either disease alone. The cost of care for a patient with both diabetes and hypertension, although not double that for a patient with diabetes or hypertension alone, was higher than the cost of treating either disease.

Entities:  

Mesh:

Year:  1999        PMID: 10478988     DOI: 10.1093/ajhp/56.15.1515

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

Review 1.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

Review 2.  Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Coincidence of diabetes mellitus and hypertension in a semi-urban Cameroonian population: a cross-sectional study.

Authors:  Jean-Claude Katte; Anastase Dzudie; Eugene Sobngwi; Eta N Mbong; Gerard Tama Fetse; Charles Kouam Kouam; Andre-Pascal Kengne
Journal:  BMC Public Health       Date:  2014-07-08       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.